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Clustered regularly interspaced palindromic repeats (CRISPR)-associated (Cas9) technology has proven a
formidable addition to our armory of approaches for genomic editing. Derived from pathways in archaea
and bacteria that mediate the resistance to exogenous genomic material, the CRISPR-Cas9 system utilizes
a short single guide RNA (sgRNA) to direct the endonuclease Cas9 to virtually anywhere in the genome.
Upon targeting, Cas9 generates DNA double-strand breaks (DSBs) and facilitates the repair or insertion of
mutations, insertion of recombinase recognition sites, or large DNA elements. Here, we discuss the practical
advantages of the CRISPR-Cas9 system over conventional and other nuclease-based targeting technologies
and provide suggestions for the use of this technology to address immunological questions.Introduction
The use of genetically modified mice provides critical insights
into the organization and function of the immune system. For
the past three decades, gene targeting by homologous recombi-
nation in embryonic stem (ES) cells has been the method of
choice for genome modification in mice (Capecchi, 2005). How-
ever, this approach is tedious, time consuming, and expensive
and cannot be applied to other mammalian species or mouse
strains with complex genetic backgrounds because of the lack
of established ES cells. To overcome these limitations, target-
able nuclease technologies such as zinc finger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs),
and, more recently, clustered regularly interspaced palindromic
repeats (CRISPR)-associated (Cas9) have been developed.
These endonucleases can be targeted virtually anywhere in the
genome of any species to introduce DNA double-strand breaks
(DSBs). Resolution of these DSBs by either non-homologous
end joining (NHEJ) or homology directed repair (HDR) then facil-
itates the introduction of random or specific mutations, repair of
endogenous mutations, or insertion of DNA elements. Unlike
conventional targeting, nuclease-based genome engineering
does not require in vitro single-cell clonal expansion and pro-
longed drug selection, which might introduce genetic mutations,
nor does it leave behind undesired exogenous DNA elements.
Moreover, nuclease-based technologies can be performed
directly in zygotes, accelerating the generation of animal models
from 12months for conventional gene targeting in ES cells to less
than a few months using CRISPR-Cas9 technology. In this re-
view, we briefly describe CRISPR-Cas9 and related technolo-
gies for genome engineering and provide guidelines for their
use in generating mouse models. We also discuss recent ad-
vances in these technologies and their use for immunological
studies.
CRISPR-Cas9 Technology
Because of its simplicity, the CRISPR-Cas9 system is rapidly
becoming the method of choice for gene targeting. Unlike
ZFNs and TALENs, both of which require the complex engineer-
ing of highly specific DNA binding domains for their proper tar-18 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.geting to genomic loci, the endonuclease Cas9 relies solely on
a small artificial RNAmolecule termed single guide RNA (sgRNA)
(Jinek et al., 2012). The sgRNA is a 100-nucleotide molecule
generated from the fusion of a CRISPR RNA (crRNA) with a
transactivating CRISPR RNA (tracrRNA) (Figure 1). The crRNA
confers sequence specificity by forming an RNA-DNA complex
with a region called the protospacer element on the target
DNA, whereas the tracrRNA interacts with Cas9 to form the ribo-
nucleoprotein. The genomic sequences receptive to CRISPR-
Cas9 targeting require the presence of a short nucleotide
sequence located 30 of the protospacer element, termed the
protospacer adjacent motif (PAM) (Figure 1B). For example,
Streptococcus pyogenes Cas9, the most commonly used Cas
endonuclease for genome editing, requires a PAM sequence
consisting of 50-NGG-30 (where N represents any nucleotide)
for optimal activity (Hsu et al., 2013). A variant of this sequence,
50-NAG-30, confers limited activity (20%) whereas any other
combinations do not (Hsu et al., 2013). Although the requirement
for PAM sequences might be viewed as a limitation to the
technology, S. pyogenes Cas9 PAM sequences are found, on
average, as frequently as every ten nucleotides in the genome
(+ and – strand combined, Table 1). Moreover, several additional
CRISPR-Cas systems from Streptococcus mutans, Strepto-
coccus thermophilus (CRISPR3), Streptococcus thermophilus
(CRISPR1), Campylobacter jejuni, Neisseria meningitidis, Pas-
teurella multocida, Francisella novicida, and Treponema denti-
cola (Table 2) have also been developed into tools for genome
engineering (Esvelt et al., 2013; Fonfara et al., 2014; Hou et al.,
2013; Zhang et al., 2013). These systems have distinct PAM
requirements and might serve as a collection of tools to cover
virtually every nucleotide within genomes from different species.
The orthogonality of these systems also allows simultaneous and
independent targeted-gene regulation and editing in the same
cell (Esvelt et al., 2013).
Limitations Associated with the CRISPR-Cas9 System
Although the CRISPR-Cas9 system provides great advantages
over conventional targeting, several potential issues must be
addressed when considering using this technology. As with
Figure 1. DNA Sequence Elements Recognized by CRISPR-Cas9
(A) Schematic representation of a single guide RNA, a synthetic RNAmolecule
resulting from the fusion of crRNA (N20, red) and the scaffolding tracrRNA
(blue). sgRNAs are required and sufficient to target the endonuclease Cas9 to
specific sequences in the genome.
(B) Schematic representation of a target DNA sequence that comprises the
protospacer element (N20, black) upstream of the protospacer adjacent motif
(PAM, NGG, blue). Arrows indicate the location of the double-strand break
introduced by the Cas9 endonuclease.
Table 1. Number and Frequency of N20NGG, Unique N20NGG,
N13NGG, and Unique N12NGG Sequence in the Mouse Genome
Sequence Number of Site
Frequency in Mouse
Genome (Number of Sites/
Number of Nucleotides)
N20NGG 274,072,490 1/10
Unique N20NGG 204,035,213 1/13
Unique N13NGG 11,369,632 1/240
Unique N12NGG 5,274,838 1/517
Mouse genome length is 2,725,765,481 nucleotides. This table was
generated by downloading the mouse genome (mm9, NCBI Build 37) in
FASTA format (chromFa.tar.gz) from http://hgdownload.soe.ucsc.edu/
goldenPath/mm9/bigZips/. All possible 20-mers followed by a PAM
sequence (NGG) were extracted with the fuzznuc tool from the EMBOSS
Suite (Rice et al., 2000). A Python script was used to convert the fuzznuc
outputs to BED files as well as extracting all 20-, 13-, and 12-mers to
separate files, with one site per line. A pipeline of the UNIX command
‘‘sort’’ and ‘‘uniq’’ was used to return unique lines.
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appropriate precautions to ensure target specificity. Several
studies have demonstrated that mismatches between crRNA
and targeted sequences can be tolerated by the Cas9 endonu-
clease (Fu et al., 2013; Hsu et al., 2013; Jinek et al., 2012; Lin
et al., 2014; Mali et al., 2013a; Pattanayak et al., 2013). Although
there are no definitive rules for Cas9 specificity, the number and
location of mismatches play a critical role. As an approximation,
DNA-RNA duplex mismatches in close proximity to the PAM
sequence impair Cas9 activity whereas mismatches distal to
the PAM sequence are tolerated. Although a single nucleotide
mismatch does not affect Cas9 activity, two or more mis-
matches, depending on their location with respect to the PAM
sequence, decrease Cas9 activity (Fu et al., 2013; Hsu et al.,
2013; Lin et al., 2014; Mali et al., 2013a; Pattanayak et al.,
2013). Several strategies have been proposed to minimize the
number of off-target cleavage events. These include the use of
double nickases (Mali et al., 2013a; Ran et al., 2013), shorter
sgRNAs (Fu et al., 2014), and a fusion protein containing a cata-
lytically inactive Cas9 and the endonuclease Fok1 (Guilinger
et al., 2014; Tsai et al., 2014). Although these strategies proved
to be helpful for gene targeting in cell lines, the careful selection
of sgRNAs is sufficient to avoid off-target cleavage in vivo (see
sgRNA selection below).
Developed for its high efficiency, CRISPR-Cas9 technology
can readily target several loci simultaneously, including both al-
leles of the same gene (Wang et al., 2013; Yang et al., 2013a;
Zhou et al., 2014). Although this represents a remarkable attribute
when modification of multiple genes is desired, it carries with it
obvious limitations when the targeted genes of choice are essen-
tial for embryonic or germ cell development. This problem can be
overcome by limiting the concentration of Cas9 mRNA transcriptfor zygotic injections, thereby reducing CRISPR-Cas9 activity to
favor heterozygosity over homozygosity.
Another limitation associatedwith nuclease-based technology
for genomemodification is the generation of mice mosaic for the
target gene. Mosaicism can occur when more than two alleles
serve as substrates for the nuclease. To avoid this problem, in-
jections should be performed as early as possible after fertiliza-
tion to increase the chances of targeting alleles at the single-cell
stage. Although the rate of mosaicism has remained relatively
low in our experience, studies have reported up to 40% mosai-
cism with this technology (Yang et al., 2013a).
Gene Targeting in Mice via CRISPR-Cas9 Technology
The basic principles of conventional gene targeting also apply to
CRISPR-Cas9 technology (Nagy, 2003). For example, the gener-
ation of a conditional allele requires careful analysis of the gene
structure for optimal insertion of loxP sites. Similarly, insertion of
transgenic DNA elements, point mutations, or deletion of chro-
mosomal segments must be carefully planned with appropriate
implementation of precautionary measures. Below, we present
examples of different types of targeting strategies (Figure 2).
Example 1: Insertion of Random Mutations
The most common and straightforward type of mutation gener-
ated by CRISPR-Cas9 technology is the insertion of randommu-
tations caused by the resolution of DSBs by NHEJ. Although this
approach has beenwidely used to target single ormultiple genes
at once (Wang et al., 2013; Yang et al., 2013a; Zhou et al., 2014),
it is important to note that random insertion or deletion of DNA
elements do not always result in gene disruption and can pro-
duce proteins with undesired and/or artificial properties.
Example 2: Point Mutations
To generate a point mutation, a single DSB is introduced near the
location of the desired mutation by means of a single sgRNA.
Resolution of the DSB by homology-directed repair is then facil-
itated by the co-injection of an HDR template. In this case, the
HDR template consists of a 200-nucleotide-long single-stranded
DNA (ssDNA) molecule that contains the desired mutation
flanked by two homology arms in addition to sequence modifi-
cations enabling detection of the altered locus and preventingImmunity 42, January 20, 2015 ª2015 Elsevier Inc. 19
Table 2. CRISPR-Cas Systems Developed for Genome Editing
and Their Cognate PAM Requirements
Species PAM References
Streptococcus pyogenes NGG Hsu et al., 2013
Streptococcus mutans NGG van der Ploeg, 2009
Streptococcus
thermophilus (CRISPR3)
NGGNG Deveau et al., 2008;
Fonfara et al., 2014;
Horvath et al., 2008
Streptococcus thermophilus
(CRISPR1)
NNAAAAW Fonfara et al., 2014
Campylobacter jejuni NNNNACA Fonfara et al., 2014
Neisseria meningitidis NNNNGATT Hou et al., 2013;
Zhang et al., 2013
Pasteurella multocida GNNNCNNA Fonfara et al., 2014
Francisella novicida NG Fonfara et al., 2014
Treponema denticola NAAAAN Esvelt et al., 2013
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The latter is particularly important when the desired mutation
lies outside of the protospacer element or PAM sequence.
Excessive cleavage by CRISPR-Cas9 and repair by NHEJ will
introduce undesired mutations such as small deletions or in-
sertions in addition to the desired one. Although 120- to 170-
nucleotide-long ssDNA oligonucleotides are typically used for
genome editing in mice (Wang et al., 2013; Yang et al., 2013a),
ssDNA oligonucleotides of various lengths (ranging from 70 to
200 nucleotides) have been used successfully in human iPSCs,
and ssDNA oligonucleotides shorter than 200 nucleotides
demonstrated similar and sometimes better efficiencies (Yang
et al., 2013b).
Example 3: Large Deletions
Targeted disruption of one or multiple contiguous genes by intra-
genic or intergenic deletions is efficient with CRISPR-Cas9 tech-
nology. Introduction of two DSBs flanking the region of interest
and their resolution by NHEJ facilitate chromosomal rearrange-
ment and exclusion of the region of interest. Deletions up to
60 kb have been generated in our hands and an apparently in-
verse correlation between the frequency and the length of the
deletion was observed, although the experiments were not de-
signed to address this question specifically. Consistent with
this, a recent study showed an inverse relationship between dele-
tion frequency and deletion size (Canver et al., 2014). In this strat-
egy, the precise location of the DSBs is less important than in
those aimed at introducing point mutations. Nevertheless, careful
attention should be given to the number and the location of po-
tential off-target loci, and off-target loci located on the same
chromosome as the intended on-target sites should be avoided.
Example 4: Conditional Alleles
The generation of mice bearing conditional alleles, regardless of
the recognition site (loxP or others), makes use of a combination
of the two previous strategies. As detailed above, DSBs are
generated on each side of a region of interest, except that in
the case of conditional allele insertion, DSBs are instead
resolved by HDR. To promote HDR over NHEJ at sites of
DSBs, two HDR oligonucleotides, each containing a loxP site
and a restriction enzyme site flanked by arms of homology
(Figure 3B), are co-injected with CRISPR-Cas9. Design of the20 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.two sgRNAs depends on a combination of the aforementioned
criteria, the options for which might be limited by accommoda-
ting the effective placement of the loxP sites. loxP site locations
are chosen to ensure appropriate disruption of the target gene
upon Cre-mediated recombination and to limit the likelihood of
potential simultaneous disruption of splice donors, acceptors,
and branch sites. As with the other approaches, appropriate
consideration of sgRNA sequences with potential off-target
events located on the on-target site chromosome or exons or in-
trons of other genes should be avoided. Of note, resolution of the
DSBs by NHEJ can produce a large deletion (example 3). Thus,
from a single injection, both conditional and conventional
knockout mice can be produced.
Example 5: Insertion of Large DNA Elements
Generation of mice with large DNA element insertions is also
possible with the CRISPR-Cas9 system (Wang et al., 2013;
Yang et al., 2013a). In this case, a single DSB is introduced at
or near the site of insertion and HDR is stimulated by co-injection
of a circular plasmid containing theDNAelement(s) to be inserted,
flanked by homology arms long enough to promote HDR
(Figure 3C). Cleavage of the targeting plasmid itself by CRISPR-
Cas9 will prevent proper targeting and instead promote random
integration of the linear DNA into the genome. Therefore, silent
mutations should be incorporated into the DNA plasmid to avoid
its recognition by CRISPR-Cas9. Moreover, in the event that
proper targeting occurs, disruption of the protospacer element
will also prevent further cleavage of the locus by CRISPR-Cas9
and generation of unwanted mutations. When preparing plasmid
DNA for microinjection, special attention should be given to
ensure that no residual RNAase remains in the preparation to
avoid degradation of Cas9 mRNA and sgRNA transcripts.
Example 6: Chromosomal Translocations
Chromosomal translocations have been clinically linked to
various forms of cancer, including leukemias, lymphomas, and
sarcomas, and mimicking such translocation in transgenic
mice has proven invaluable to our understanding of cancer
biology. CRISPR-Cas9 technology enables the generation of
such clinically relevant translocations, although feasibility of
this approach is limited. In this case, DSBs are introduced in sites
within both chromosomes of interest. To promote chromosomal
translocation, an HDR oligonucleotide with sequence homology
to both chromosomal loci is then co-injectedwith CRISPR-Cas9.
Although this approach has been successful in cell lines, only 2%
of the cells exhibited the appropriate recombination event
(Torres et al., 2014). We are not aware of this approach being at-
tempted in vivo.
Example 7: Targeting Identical Genetic Elements
In addition to targeting single-copy genes, CRISPR-Cas9 tech-
nology can be applied to gene families in which genes share
identity in some regions, such as those encoding major histo-
compatibility molecules, antigen receptors, and pattern recog-
nition receptors. A single sgRNA-HDR template pair can be
designed to disrupt several or all of the genes in a family or sub-
family based on highly conserved sequences. Such a strategy
has not been reported.
Example 8: Insertion of SNPs
SNPs are the most abundant genetic variations in individuals and
are, in some instances, causally linked to disease susceptibility
and severity and to responses to pharmacological treatments.
Figure 2. Targeting Strategies Used to
Introduce Various Types of Mutations by
CRIPSR-Cas9 Technology
Examples 1 and 7 (insertion of random mutations
and targeting identical genetic elements) make use
of a single sgRNA together with Cas9 to target
a single copy or multiple copy number genes.
Resolution of the DSB(s) by NHEJ will result in
the generation of several genetic modifications,
including nonsense, missense, or various de-
letions. Example 2 (point mutations) makes use of
a sgRNA together with Cas9 and an ssDNA oligo-
nucleotide to facilitate HDR. Resolution of the DSB
by HDR will result in the introduction of the desired
mutation (P). Example 3 (large deletions) makes
use of two sgRNAs flanking a region of interest.
Resolution of the DSBs by NHEJ will result in the
deletion of the region of interest. Example 4 (con-
ditional alleles) also makes use of two sgRNAs
flanking a region of interest, Cas9 and Cas2 ssDNA
oligonucleotides, to facilitate HDR. Resolution of
DSBs by HDR will introduce loxP sites at the
desired locations. Example 5 (insertion of DNA el-
ements) makes use of one sgRNA, Cas9, and a
circular plasmid or ssDNA oligonucleotide. Reso-
lution of DSBs by homologous recombination will
introduce the DNA elements. Example 6 (chro-
mosomal translocations) makes use of two
sgRNAs designed to introduce DSBs on separate
chromosomes (Ch1 and Ch2) together with Cas9
and a single ssDNA with sequence complemen-
tarity flanking the translocation break. Example 8
(targeting SNPs) makes use of a single degenerate
sgRNA containing one or two mismatches with its
target sequence. Resolution of the DSB by HDR
will introduce a single-nucleotide mutation. The
newly form sites, now having an extra mismatch,
might no longer be recognized by the degenerate
sgRNA-Cas9 ribonucleoprotein complex and
cleaved again, allowing the insertion of a SNP.
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generate nonsense mutations or missense mutations that can
directly affect the function of the gene product. When located in
regulatory regions of a gene, SNPs can also have dramatic effects
by influencing gene expression, mRNA conformation and stabil-
ity, and/or localization within cells (Capon et al., 2004; Kimchi-
Sarfaty et al., 2007; Nackley et al., 2006). Faithful reproduction
of these variations in cells or animal models is therefore important
for our understanding of diseases associated with specific SNPs.
Generation of SNPs by CRISPR-Cas9 technology, however,
might prove to be difficult because of the tolerance of Cas9 for
base-pairing mismatches between the sgRNA and its cognateImmunity 4protospacer element. The newly gener-
ated allele with only one base pair
mismatch might continue to serve as a
substrate for Cas9 and therefore be
cleaved repeatedly until repaired by
NHEJ. To circumvent this limitation, a de-
generate sgRNA containing one or two
mismatches for the target site can be
substituted for the conventional, perfectly
paired, sgRNA. After the introduction of
the DSB at the desired site and repair by
HR via an ssDNA oligonucleotide, the re-
paired allele would now have an extrabase pair mismatch. In principle this would prevent further cleav-
age of the target site. This strategy is a feasible approach to
directly assess the role of particular SNPs in vivo.
sgRNA Selection
The successful implementation of CRISPR-Cas9 technology is
entirely dependent upon selecting the appropriate sgRNA(s) to
achieve the modification of choice. The selection of sgRNAs de-
pendson the typeofmutation tobegeneratedand the target spec-
ificity of the sgRNA. Several open-access websites now provide
tools for the identification of on- and off-target loci. These include
CRISPR Design (http://crispr.mit.edu/), E-CRISP (http://www.2, January 20, 2015 ª2015 Elsevier Inc. 21
Figure 3. Homology-Directed Repair Templates
(A) 200-nucleotide-long ssDNA oligonucleotides are used to introduce point
mutations with CRISPR-Cas9 technology. The ssDNA contains the desired
mutations (P, green) flanked by 60- to 90-nucleotide-long sequences homol-
ogous to the genomic target locus (not shown). Silent substitutions (X, red) are
also introduced to facilitate the detection of the mutant allele, including mu-
tations that disrupt or insert restriction enzyme sites. It is not always possible to
insert the desired mutations within the protospacer element. Therefore, to
avoid successive cleavage by Cas9 and introduction of internal deletion/
insertion by NHEJ, additional silent mutations are introduced within the HDR
oligonucleotide to alter the protospacer element or the PAM sequence.
(B) Insertion of recombinase recognition sites or epitope tags within the
genome also relies on 200-nucleotide-long single-stranded oligonucleotides
containing the recombinase recognition sequence (loxP, green) and a re-
striction enzyme recognition sequence (green underlined) flanked by 80-
nucleotide-long sequence homologous to the genomic target locus (not
shown). The insertion of a restriction site will facilitate detection of the allele by
PCR and Southern blot analyses. Recombinase recognition sites are inserted
three nucleotides upstream of the PAM sequence, disrupting the protospacer
element upon HDR and preventing further cleavage by Cas9. Because the
insertion site of epitope tags might fall outside of the protospacer element or
the PAM sequence, additional mutations within the protospacer element or the
PAM sequence are introduced (not shown).
(C) Circular plasmids are used to introduce larger DNA elements such as green
fluorescent proteins. These plasmids contain the DNA element flanked by
large homology arms of 500 to >2,000 base pairs (blue). If the insertion site lies
outside of the protospacer element or the PAM sequence, additional sub-
stitutions should be also introduced to prevent further cleavage by Cas9 and
introduce undesirable mutations.
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partners.org/ZiFiT/), and Cas-OFFinder (http://www.rgenome.
net/) (Bae et al., 2014). These websites accept a wide range of in-
puts, identify potential on-target sites, and generate a list of poten-
tial off-target loci for each on-target locus. However, caution
should be exercised because some of these web-based CRISPR
tools fail to identify all possible off-target loci and/or to provide
critical information such as their chromosomal location and posi-
tion relative to known genes (exonic, intronic, or intergenic).22 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.While implementing CRISPR-Cas9 technology for mouse
genome editing in our laboratory, we developed a strategy for
the selection of sgRNAs allowing optimal flexibility and efficacy.
Based on studies of CRISPR-Cas9 specificity in cell lines (Cong
et al., 2013; Fu et al., 2013; Hsu et al., 2013; Jiang et al., 2013;
Jinek et al., 2012; Mali et al., 2013b), our strategy combines
the use of several web-based CRISPR-Cas9 tools and takes
into account the original observations that several mismatches
(up to eight) located at the 50 end of the sgRNA can be tolerated
by S. pyogenes Cas9 (Jinek et al., 2012). The details of our pro-
cedure are presented in Box 1.
As an alternative to this strategy, the CRISPR Design web tool
can also be used for sgRNA target site identification. However,
caution is advised because this web-based resource does not
always return the complete list of all possible off-target sites
associated with given sgRNA. Similarly, we do not recommend
using a traditional algorithm such as BLAST (Altschul et al.,
1990) for the identification of off-target loci because this fails to
return all possible results. Instead, we recommend using Fuzz-
nuc from EMBOSS Suite (Rice et al., 2000) or Bowtie (Langmead
et al., 2009) which, unlike BLAST, search the input pattern base
by base, returning all possible hits.
Preparation of Reagents for Zygotic Injections
Injection of CRISPR-Cas9 directly into pronuclear-stage zygotes
has greatly accelerated the generation of genetically modified
mice (Wang et al., 2013; Yang et al., 2013a, 2014). The approach
consists of microinjecting human-codon-optimized Cas9 mRNA
transcripts, sgRNA transcripts, and HDR templates directly into
pronuclear-stage zygotes. Upon translation, sgRNA-loaded
Cas9 translocates to the nucleus and introduces DSBs. The con-
centrations of reagents used are typically as follows: Cas9
mRNA transcript, 100 ng/ml; sgRNA, 50 ng/ml; HDR oligonucleo-
tides, 200 ng/ml; and circular plasmids, 200 ng/ml.
As an alternative to RNA transcript injection, recent studies
showed that microinjection of circular plasmids encoding the hu-
man-codon-optimized Cas9 and sgRNAwas equally efficient for
introducing DSBs in zygotes (Mashiko et al., 2013). However, 2
out of the 46 pups also integrated the Cas9-encoding plasmid
(Mashiko et al., 2013), which might have undesirable effects
over the phenotype. As an alternative to Cas9mRNA or cDNA in-
jections, Cas9 protein can be used. In zebrafish, Cas9 protein
microinjection in one-cell-stage embryos was equally effective
in generating DSBs and, in some cases, increased mutagenic
activity (Gagnon et al., 2014). The use of Cas9 protein in lieu of
the Cas9 transcript for zygotic injectionsmight prove to be useful
to reduce mosaicism resulting from delayed translation of Cas9
mRNA into a functional entity. In the zygotes, transcription and
translation are greatly attenuated until the first cell division (Oh
et al., 2000), delaying even more Cas9 endonuclease translation
and activity to the two-cell-stage embryo, at which point four al-
leles are present. Second, it might facilitate insertion of large
DNA elements by directly injecting the ribonucleoprotein com-
plex together with large circular plasmids directly in the pronu-
clei. Third, it might limit off-target activity by reducing the dura-
tion of Cas9 activity. This approach is now being tested in
mammalian zygotes.
To introduce pointmutations or insertion of short DNA elements
(e.g., loxP sites) and to avoid random integration into the genome,
Box 1. sgRNA Selection for Mouse Genome Engineering
The first step consists of identifying unique 12-nucleotide-long sequences followed by a PAM (N12NGG) in a given region of inter-
est. Unique N12NGG can be easily visualized in the UCSC genome browser using the older UCSC Genome Browser tracks (http://
www.genome-engineering.org/crispr/?page_id=41). Unique N12NGG sites, however, are relatively rare in genomes and may not
always be found in the region of interest (Table 1). If no suitable N12NGG sites are identified, genomic sequences having unique 13-
nucleotide-long sequences followed by a PAM sequence (unique N13NGG sites) are instead selected. Although N12NGG and, even
more so, N13NGG sequences are not always predictive of Cas9 specificity (Fu et al., 2014; Hsu et al., 2013; Lin et al., 2014), the
identification of these sequences provides more flexibility for the identification of potential on-target loci and avoids obvious off-
target effects. To identify these unique N13NGG, we recommend using E-CRISP or Cas-OFFinder. In our experience, E-CRISP and
Cas-OFFinder return lists of all potential off-target loci together with important information such as chromosome location and posi-
tioning of the loci relative to known genes. Again, if no unique N13NGG are identified in the vicinity of the intended target region,
genomic sequences with non-unique N13NGG can instead be used as targets. Importantly, however, these additional N13NGG loci
might also serve as substrates for Cas9 and should be considered as potential off-target loci.
The second step in identifying suitable target sites consists of identifying, for each unique N12NGG or N13NGG sequence, all
possible off-target loci in the context of the full-length target sites (N20NRG, where R represents A or G). Again this can be easily
performed with E-CRIPSP or Cas-OFFinder. Putative on-target sites (N20NRG) having more than 90% homology (2 mismatches)
with other genomic loci are discarded whenever possible. On-target sites with less than 85% homology (3 mismatches or more)
with other genomic loci are conserved and suitable for sgRNA design. This cutoff has been selected based on previous analyses
showing that off-target loci having 3 or more mismatches are rarely, if ever, targeted by CRISPR/Cas9 in vivo mutations (Mashiko
et al., 2013; Wang et al., 2013; Yang et al., 2013a). These on-target sites are then used for the design of the sgRNAs. As
mentioned above, each sgRNA is composed of a crRNA molecule with sequence homology to the on-target site (N20) fused
to a tracrRNA. PAM sequences are uniquely found at the target sites and should not be incorporated into the sgRNA molecule
itself.
The following describes the step-by step procedure used in our laboratory for the selection of sgRNAs via the Cas-OFFinder
(http://www.rgenome.net) website.
1. Copy and paste target region of interest into the Microhomology-associated score calculator query box and submit your
request. This will return a list of all putative target sites within your target region. Copy this list to an Excel spreadsheet and
discard any information concerning the microhomology scores. Keep only the list of target sites.
2. In a new column, copy and paste the list of potential target sequences and trim off the PAM (NGG) located at the 30 end of the
sequences (N20).
3. Copy and paste the N20 sequences in a new column titled N12NGG and replace the first eight nucleotides of each sequence by
N (which represents any nucleotides). These represent all possible N12NGG in the target sequence.
4. Copy and paste the N12NGG list into the Query sequences. Choose the appropriate parameters. For example: SpCas9 from
Streptococcus pyogenes: 50-NGG-30. Target genome:Musmusculus (mm10) –Mouse. Set the number ofmismatches to 0 and
press submit. This will return a list of all loci containing identical N12NGG sequences.
5. Copy and paste this list in the Excel spreadsheet under a new tab entitled ‘‘Unique N12NGG.’’
6. Generate a pivot table from these data and identify the number of off-target sequences for each of the N12NGG sequences.
Sequences with only one instance can be used for sgRNA design and continue with step 9.
7. If no unique N12NGG sequences are identified, copy and paste the N20 sequences in a new column entitled N13NGG and
replace the first seven nucleotides of each sequence by N (which represents any nucleotides) and repeat steps 4, 5, and 6.
8. If no unique N13NGG can be identified, a sgRNA with non-unique N13NGG sequence can be used. However, the additional
sites with perfect N13NGG matches should be considered as potential off-target loci.
9. Whenever possible, select sgRNAs having unique N12NGG or N13NGG.
To identify potential off-target loci of sgRNAs having unique or non-unique N12NGG or N13NGG, copy and paste their corre-
sponding N20 sequences in the Cas-OFFinder application under Query sequences. Choose the appropriate parameters, for
example: SpCas9 from Streptococcus pyogenes: 50-NRG-30 (R = A or G); Target genome: Mus musculus (mm10) – Mouse. Set
the number of mismatches to four and press submit. This will return a list of all potential off-target loci for a given sgRNA. Strategies
for cloning and expression of Cas9 mRNA and sgRNAs are outlined in Figures S1 and S2.
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Review200-nucleotide-long oligonucleotides are co-injected with
CRIPSR/Cas9. Insertion of larger DNA elements such as green
fluorescent proteins makes use of circular plasmids to prevent
random integration. Linear DNA molecules integrate the genome
at higher frequency than circular DNA (Brinster et al., 1985).
Both cytosolic and nuclear injections of reagents in zygotes
have been shown to be efficient for introducing DSBs (Horii
et al., 2014; Wang et al., 2013; Yang et al., 2013a; Zhou et al.,2014). For mouse strains that are not amenable to superovula-
tion or mice with complex genetic backgrounds, injection can
also be performed in in vitro fertilized eggs as demonstrated
recently (Li et al., 2014).
Characterization of CRISPR-Cas9-Engineered Animals
The genome of mice obtained from zygotic injections is charac-
terized by a combination of approaches. The on-target locus isImmunity 42, January 20, 2015 ª2015 Elsevier Inc. 23
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ReviewPCR amplified by means of primers flanking the locus and
directly sequenced and/or digested with the specified restriction
enzyme (when restriction sites are inserted or deleted by HDR).
The desired restriction pattern, however, does not necessarily
indicate the presence of the intended mutation. Additional frame
shift mutations or reorganizations might occur. Sequencing is
therefore required to ascertain that the repair occurred as
planned. Moreover, direct sequencing of the PCR product might
yield inconclusive results because of the presence of multiple al-
leles. Thus, PCR amplicons are TOPO cloned and a minimum of
30 clones sequenced for each mouse. TOPO cloning of PCR
fragments also provides information on possible mosaicism at
the target locus. For large deletions, primers flanking the region
of interest are used to detect a recombined allele. Direct se-
quencing of this PCR product also provides information
regarding the nature and location of the DNA breaks and rear-
rangements. One of the challenges in generating mice bearing
a conditional allele generated by CRISPR-Cas9 technology is
to ensure the successful introduction of recombinase recogni-
tion sequences (i.e., loxP sites) on the same allele. To ascertain
that loxP sites are indeed present on the desired allele, Southern
blot analyses might be required (especially when loxP sites are
located several thousands of base pairs apart). In addition, in
some cases, analysis of the F1 progeny might be required to
determine that the two loxP sites are chromosomally linked.
Mice with the desired modifications are then analyzed for po-
tential off-target alterations. To identify all potential off-target
loci, we recommend using E-CRISP or Cas-OFFinder, searching
for N20NRG sequences with one to three mismatches, because
these web tools use Bowtie (Langmead et al., 2009) which re-
turns all possible hits. Also, as mentioned above, if non-unique
N13NGG target sequences are used as templates for sgRNAs,
these additional target sites should be considered as potential
off-target loci. Although there is no evidence that off-target loci
having three or more mismatches are cleaved in vivo (Mashiko
et al., 2013;Wang et al., 2013; Yang et al., 2013a), these potential
off-target sequences should, nonetheless, be analyzed by PCR
amplification and direct sequencing. The number of off-target
cleavage sites has remained very low in studies using zygotic in-
jection of CRISPR-Cas9 for mouse genome engineering. Only
off-target loci with one or two mismatches contained mutations.
Mice with off-target modifications are either discarded or bred to
wild-type mice to eliminate the undesired mutation(s). In this
case, careful analysis of the F1 progeny is required prior to es-
tablishing the colony to ensure that non-desirable mutations
are no longer present.
The successful use of zygotic injections of CRISPR-Cas9 to
generate mice with appropriate mutations varies depending
upon the type of mutation generated. The rate of random inser-
tion/deletions (NHEJ) at any particular site is astonishingly high,
reaching up to 100% of the alleles in some cases. Introduction of
point mutations by HDR occurs in 10%–70%of the alleles. Large
deletion frequency using pairs of sgRNAs are found in 15%–65%
of mice and this strategy has become our standard method for
gene ablation. Introduction of loxP sites or large DNA elements,
however, is less efficient, with fewer than 20%of themice having
the proper recombination events (Yang et al., 2013a).
When ssDNA oligonucleotides are used to induce HDR, addi-
tional mutations in the vicinity of the desired mutations are24 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.sometimes found. It is unclear whether these additional muta-
tions come from the ssDNA oligonucleotide itself or from micro-
deletions, insertions, or mutations that occur during the DNA
repair process. Nevertheless, this observation underscores
the critical importance of performing thorough analyses of
founder mice.
Mouse Mutation Nomenclature
Once new mouse lines have been generated, they should be
named in accordance to the Guidelines for Nomenclature of
Genes, Genetic Markers, Alleles, and Mutations in Mouse
and Rat from the International Committee on Standardized
Genetic Nomenclature for Mice (http://www.informatics.jax.
org/mgihome/nomen/index.shtml). We also propose that the na-
ture and the precise location of themutation be clearly described
according to the guidelines of the Human Genome Variation
Society (http://www.hgvs.org/mutnomen/) (den Dunnen and An-
tonarakis, 2000).
Use of CRISPR-Cas9 Technology for
Immunological Studies
Amenable to all species,CRISPR-Cas9 technologycan introduce
mutation(s) in any mouse strain, avoiding expensive and lengthy
backcrossing and problems inherent to backcrossing such
as the presence of single-nucleotide polymorphisms or other
genomic variants located in the vicinity of themutation of choice.
One such example is theCasp11/Casp1 conundrum in innate im-
munity.Casp1, which encodesCaspase-1 (Casp1), was targeted
in 129 ES cells, which already contained a inactivating mutation
in the Casp4 gene encoding Caspase-11 (Casp11). Casp11 is
located immediately downstream of Casp1 and could not be
segregated by recombination. Thus, some of the functions origi-
nally attributed toCasp1are nowknown tobeCasp11dependent
(Kayagaki et al., 2011). Similarly, strains with complex genetic
backgrounds, such as the non-obese diabetic (NOD)-Rag1/
Il2rg/ (NRG) mouse and the NOD-SCID; Il2rg/ (NSG) mouse,
can be directly targeted (Li et al., 2014). This is particularly useful
for immunologic studies, where cell transfer experiments are
often desirable and can produce artifacts if performed with
mice with incomplete backcrossing. Genome sequences of
several strains, including the NODmouse genome, can be found
at http://www.sanger.ac.uk/resources/mouse/genomes/.
CRISPR-Cas9 technology has been used to generate a variety
of immunodeficient mouse strains by introducing small deletions
in genes essential for the development and function of the im-
mune system (Zhou et al., 2014). Because this approach can
target multiple genes simultaneously (Wang, et al., 2013), several
immunologic genes of interest can be deleted in a single zygote.
For example, sgRNAs targeting one exon each of B2m, Il2rg,
Prf1, Prkdc, and Rag1 were injected into zygotes, resulting in
all combinations of deletions, including quintuple deletions of
all five genes, with the expected effects on immune functions
(Zhou et al., 2014). Clearly, the simultaneous targeting of multiple
genes has direct application to the generation and investigation
of complex genetic events, such as those invoked formany auto-
immune syndromes. These syndromes are thought to result
from either a single causative allele or multi genic causes. Faith-
ful reproduction of these mutations in mice or other species
would greatly benefit our understanding of the origin and the
Immunity
Reviewprogression of these diseases and perhaps the development of
better therapeutics.
CRISPR-Cas9 technology can also be used tomanipulate viral
genomes, thereby facilitating the study of viral gene functions
and perhaps generation of attenuated viruses for vaccination
(Bi et al., 2014). The potential for therapeutic intervention against
HIV-1 infections, by targeting C-C chemokine receptor type 5
gene, has also been tested in vitro and showed promising results
(Cradick et al., 2013). More recently, researchers used CRISPR-
Cas9 to target HIV-1 in latently infected microglial, pro-mono-
cytic, and T cells (Hu et al., 2014). This might be used in com-
bination with antiretroviral therapy to impair viral reactivation
events from integrated HIV-1 genes.
In addition to simplifying and accelerating the process of gene
targeting in vivo, CRISPR-Cas9 technology can be applied to
large-scale in vitro screens of diverse immunological phenom-
ena with lentiviral vector-based sgRNA libraries for mouse and
human genes being available (Sanjana et al., 2014). Moreover,
the repurposing of the CRISPR-Cas9 system into RNA-guided
transcriptional activators (CRISPRa) or repressors (CRISPRi)
(Cheng et al., 2013; Gilbert et al., 2013) allows not only large-
scale loss-of-function studies but also gain-of-function studies.
In these systems, an endonuclease-inactive Cas9 is fused to
transcriptional activators or repressors and sgRNA-guided tiling
of these fusion proteins allows graded gene expression or sup-
pression. A combination of these systems has been elegantly
applied to identify genes that control cell growth and pathways
governing responses to cholera-diphtheria fusion toxin (Gilbert
et al., 2014).
Fusion of endonuclease-inactive Cas9 (dCas9) to RNA-guided
DNA, histone, and chromatid-modifying enzymes might be use-
ful for the study of epigenetics and its role in cancer, neurological
disorders, and autoimmune diseases (Portela and Esteller, 2010)
including rheumatoid arthritis (Javierre et al., 2008; Karouzakis
et al., 2009; Vanden Berghe et al., 2006), systemic lupus erythe-
matosus (SLE) (Javierre et al., 2010), immunodeficiency, centro-
meric instability and facial anomalies (ICF) syndrome (Jin et al.,
2008), and type 1 diabetes (Miao et al., 2008).
Other applications of CRISPR-Cas9 can be envisioned. A
light- or ligand-induced heterodimerization of split Cas9 could
be developed based on previously established systems such
as the photoactivatable CIB1-CRY2 dimerization system (Ken-
nedy et al., 2010) or the ligand-induced heterodimerization
AP21967-DmrA and -DmrC binding domains system. This would
permit inducible activation of Cas9 in cells expressing suitable
sgRNAs in order to evaluate effects of acute targeting in tissues
of interest.
Alternatively, the fusion of fluorescent proteins to orthogonal
Cas proteins might allow multi-color/multi-locus capabilities
and might allow real-time imaging of the recombination events,
such as those of the Igh, Igk, Igl, Tcra, and Tcrb loci during B
and T cell development.
Technologies to directly modify or visualize RNA molecules in
cells have been limited. Cas Repeat-associated mysterious pro-
teins (RAMP) module proteins identified in Pyrococcus furious
and Sulfolobus solfataricus, which target RNA molecules guided
by small CRISPR RNAs, could be modified to serve this purpose
(Hale et al., 2008, 2009, 2012). This would permit modification
and/or visualization of mRNAs in cells of interest.Concluding Remarks
In addition to becoming a method of choice for mouse genome
engineering, CRISPR-Cas9 technology also holds great promise
for gene therapy. Adoptive transfer of genetically engineered
lymphocytes for the treatment of cancer, for example, could
greatly benefit from the CRISPR-Cas9 technology because it
is non-invasive and no residual pro-inflammatory exogenous
DNA elements such as vector backbones are generated. Clearly,
the successful clinical application of this technology must be
carefully considered in the context of potential undesirable ef-
fects. This includes the obvious challenge of ensuring limited
off-target cleavage frequency. Perhaps mechanistic studies
will provide key information regarding Cas9 specificity and sug-
gest ways to improve potential clinical efficacy.
The potential applications of CRISPR-Cas9 technology are
evolving rapidly. Clearly, the opportunities for disrupting, modi-
fying, and visualizing genetic and epigenetic events hold incred-
ible promise for advancing our understanding of fundamental
biology, including but not limited to that of the immune system.
As we have been empowered by advances in sequencing, the
application of this astonishing new technology will open hereto-
fore unimagined ways to explore, and ultimately engineer, bio-
logical events.
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